NASDAQ:ADLR - Adolor Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Adolor Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pain and pain-management products. ENTEREG (alvimopan) is the United States Food and Drug Administration (FDA) approved product. ENTEREG is indicated to accelerate upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. The Company is conducting two Phase 2 clinical trials of ADL5945 to treat opioid-induced constipation (OIC), a condition that often results from long-term use of opioid analgesics in the management of chronic pain conditions. In addition, it is continuing development efforts on ADL7445, a second peripherally-acting mu opioid receptor antagonist, which is considered a back-up compound in its OIC program. The Company has completed Phase 1 clinical evaluation of ADL6906 (beloxepin). In December 2011, Cubist Pharmaceuticals, Inc. acquired Adolor Corporation.

Receive ADLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ADLR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:ADLR
Previous Symbol
CUSIPN/A
Phone+1-302-6587581

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Adolor (NASDAQ:ADLR) Frequently Asked Questions

What is Adolor's stock symbol?

Adolor trades on the NASDAQ under the ticker symbol "ADLR."

Has Adolor been receiving favorable news coverage?

Media headlines about ADLR stock have been trending somewhat positive recently, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Adolor earned a news impact score of 0.8 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Adolor?

Shares of ADLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adolor's official website?

The official website for Adolor is http://www.adolor.com/.

How can I contact Adolor?

Adolor's mailing address is 700 Pennsylvania Dr, EXTON, PA 19341-1129, United States. The biopharmaceutical company can be reached via phone at +1-302-6587581.


MarketBeat Community Rating for Adolor (NASDAQ ADLR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  43 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  74
MarketBeat's community ratings are surveys of what our community members think about Adolor and other stocks. Vote "Outperform" if you believe ADLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADLR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel